I don't dispute anything in your post, in fact I basically agree.
The issue is that you could have said almost the same thing for the last 2 years. Nuvaring generic was supposed to launch in 2019. It's not even approved yet. Nextstellis should be a game changer but confidence in management's ability to make it all happen has been shot to pieces because of their historical performance. We're all hoping that this time is different but long term holders have been burnt too many times by this management team to count on anything until it actually happens.
Ann: Change of Director's Interest Notice, page-12
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.48 |
Change
0.070(1.59%) |
Mkt cap ! $381.1M | |||
| Open | High | Low | Value | Volume |
| $4.43 | $4.54 | $4.42 | $1.026M | 230.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 154 | $4.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.50 | 16238 | 2 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |